216080.KQ
JETEMA, Co., Ltd.
KOE · Healthcare · Biotechnology · KR
KRW 6,420.00
+3.88%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 76.6B | 76.9B | 68.5B | 58.7B | 46.0B |
| Cost of Revenue | 43.2B | 43.2B | 35.1B | 30.4B | 25.5B |
| Gross Profit | 32.7B | 33.7B | 33.4B | 28.3B | 20.5B |
| Operating Expenses | |||||
| R&D Expense | 9.5B | 10.0B | 9.8B | 10.2B | 6.3B |
| SG&A Expense | 17.5B | 8.9B | 8.4B | 7.1B | 5.7B |
| General & Admin Expense | 9.1B | 2.1B | 1.9B | 1.3B | 938.2M |
| Selling & Marketing Expense | 5.4B | 6.7B | 6.5B | 5.8B | 4.8B |
| Other Expenses | 7.6B | 11.0B | 11.1B | 8.4B | 6.3B |
| Total Operating Expenses | 29.6B | 29.9B | 29.3B | 25.7B | 18.3B |
| Cost and Expenses | 72.8B | 73.1B | 64.4B | 56.1B | 42.0B |
| Operating Income (EBIT) | 3.8B | 3.8B | 4.1B | 2.6B | 4.0B |
| Non-Operating | |||||
| Interest Income | 132.3M | 310.6M | 479.8M | 267.0M | 410.7M |
| Interest Expense | 8.2B | 10.6B | 12.1B | 12.9B | 9.6B |
| Net Interest Income | (8.1B) | (10.3B) | (11.6B) | (12.6B) | (9.2B) |
| Other Non-Op Income/Expense | (5.7B) | (11.5B) | (9.8B) | (1.6B) | (2.1B) |
| Non-Operating Income (excl Interest) | (10.3B) | — | (2.3B) | (11.3B) | (9.0B) |
| EBT (Pre-Tax Income) | (1.9B) | (7.7B) | (5.7B) | 1.1B | 1.9B |
| Income Tax Expense | 23.7M | (252.6M) | (3.1B) | (12.5B) | 429.3M |
| Bottom Line | |||||
| Net Income | (1.3B) | (6.6B) | (188.3M) | 14.0B | 1.5B |
| Earnings from Cont. Ops | (1.9B) | (7.4B) | (2.6B) | 13.6B | 1.5B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (1.3B) | (6.6B) | (188.3M) | 14.0B | 1.5B |
| Per Share | |||||
| Basic EPS | (₩39) | (₩184) | (₩5) | ₩196 | ₩41 |
| Diluted EPS | (₩39) | (₩184) | (₩5) | ₩68 | ₩41 |
| Revenue Per Share | ₩2,055 | ₩2,136 | ₩1,918 | ₩3,293 | ₩2,585 |
| Shares | |||||
| Basic Shares Outstanding | 37.3M | 36.0M | 35.7M | 17.8M | 17.8M |
| Diluted Shares Outstanding | 37.3M | 36.0M | 35.7M | 19.4M | 18.0M |
| Profitability Metrics | |||||
| EBITDA | 20.4B | 12.4B | 15.5B | 22.4B | 16.9B |
| D&A | 8.4B | 8.6B | 9.1B | 8.4B | 4.9B |
| EBIT | 11.9B | 3.8B | 6.4B | 13.9B | 12.0B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026